Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Inspection Record
GlaxoSmithKline Biologicals SA — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Input to and output from the computer and related systems of formulas are not checked for accuracy.
Deviations from written production and process control procedures are not justified.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Lonza Biologics, Inc.2026-04-16 · US FDASimilar to finding 1 Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength…
- Cipla Limited2024-06-21 · US FDASimilar to finding 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Patheon Italia S.p.A.2023-05-26 · US FDASimilar to finding 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Maiva Pharma Private Limited2026-02-20 · US FDASimilar to finding 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Gland Chemicals Private Limited2025-11-27 · US FDASimilar to finding 2 Aseptic processing areas deficient regarding system for monitoring environmental conditions.
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.